System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 2 citations

PubMed: 39294397 DOI: 10.1007/s10238-024-01484-z

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.

Clin Exp Med 24(1):223

Authors: Abhibroto Karmakar, Uma Kumar, Smitha Prabhu, Vinod Ravindran, Shankar Prasad Nagaraju, Varashree Bolar Suryakanth, Mukhyaprana M Prabhu, Subhradip Karmakar

Affiliations

  • Department of General Medicine, Kasturba Medical College, Manipal, Manipal Academy Higher Education, Manipal, India.
  • Department of Rheumatology, All India Institute of Medical Sciences New Delhi, New Delhi, India.
  • Department of Dermatology, Kasturba Medical College, Manipal Academy Higher Education, Manipal, India.
  • Department of Rheumatology, Centre for Rheumatology, Kozhikode, Kerala, India.
  • Department of Nephrology, Kasturba Medical College Manipal, Manipal Academy Higher Education, Manipal, India.
  • Department of Biochemistry, Kasturba Medical College Manipal, Manipal Academy Higher Education, Manipal, India.
  • Department of General Medicine, Kasturba Medical College, Manipal, Manipal Academy Higher Education, Manipal, India.
  • Department of Biochemistry, All India Institute of Medical Sciences New Delhi, New Delhi, India.

Abstract

Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life. Despite several attempts to comprehend the pathogenesis of SLE, knowledge about the precise molecular mechanisms underlying this disease is still lacking. The current treatment options for SLE are pragmatic and aim to develop composite biomarkers for daily practice, which necessitates the robust development of novel treatment strategies and drugs targeting specific responsive pathways. In this communication, we review and aim to explore emerging therapeutic modalities, including multiomics-based approaches, rational drug design, and CAR-T-cell-based immunotherapy, for the management of SLE.

MeSH

Pharmaceutical Preparations, Lupus Erythematosus, Systemic, Clinical Medicine, Therapeutics